<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68969">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02113540</url>
  </required_header>
  <id_info>
    <org_study_id>Grant number: 392172</org_study_id>
    <nct_id>NCT02113540</nct_id>
  </id_info>
  <brief_title>Assessment of the Effect of Atorvastatin on Prevention of CIN in Patients Undergoing Coronary Angiography</brief_title>
  <acronym>CIN</acronym>
  <official_title>Atorvastatin and Prevention of Contrast Induced Nephropathy Following Coronary Angiography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Isfahan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Isfahan University of Medical Sciences</source>
  <oversight_info>
    <authority>Iran: Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      As the effect of statin use before the angiography to prevent contrast induced nephropathy
      (CIN) is not well-known, the aim of the current study is to assess the effect of
      atorvastatin on prevention of CIN in patients undergoing coronary angiography.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Contrast induced nephropathy (CIN) incidence</measure>
    <time_frame>48 hours after the procedure</time_frame>
    <description>CIN is determined as an increase in post-procedural serum creatinine of &gt; 0.5 mg/dl or &gt; 25% from baseline in the absence of any other causes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum creatinine (Cr) level</measure>
    <time_frame>48 hours after the procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <condition>Contrast Induced Nephropathy</condition>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>taking atorvastatin like placebo 12 hours before the procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>long term statin group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>taking atorvastatin for a long time before entering the study (their routine treatment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>preoperation statin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>taking atorvastatin 12 hours before the procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <arm_group_label>preoperation statin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  having chronic stable angina who were referred for coronary angiography

          -  non-pregnant female subjects

          -  no history of diabetes mellitus

          -  no history of renal failure

          -  no history of single kidney

          -  no history of cardiogenic shock

          -  no history of unstable angina

          -  no history of myocardial infarction

          -  no history of hypersensitivity to statins

          -  no history of previous intravascular contrast injection during one month before
             admission

        Exclusion Criteria:

          -  glomerular filtration rate (GFR) &lt;60

          -  cardiogenic shock
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Isfahan</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>payman bidram, resident, MD</last_name>
      <phone>0989131102802</phone>
      <email>pbidram2000@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 10, 2014</lastchanged_date>
  <firstreceived_date>April 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Isfahan University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>peyman bidram</investigator_full_name>
    <investigator_title>Dr peyman bidram</investigator_title>
  </responsible_party>
  <keyword>coronary angiography</keyword>
  <keyword>chronic stable angina</keyword>
  <keyword>CIN</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
